We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+10.59%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$927M
AUM Growth
-$316M
Cap. Flow
-$340M
Cap. Flow %
-36.68%
Top 10 Hldgs %
46.63%
Holding
71
New
14
Increased
9
Reduced
19
Closed
16

Top Buys

Rank Stock Value
1
CLDX icon
Celldex Therapeutics
CLDX
+$34.3M
2
PCVX icon
Vaxcyte
PCVX
+$27M
3
CYTK icon
Cytokinetics
CYTK
+$22.3M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$21.8M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$20.9M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$58.1M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$33M
3
XNCR icon
Xencor
XNCR
+$28.4M
4
SLN
Silence Therapeutics
SLN
+$23.7M
5
VERA icon
Vera Therapeutics
VERA
+$17.1M

Sector Composition

Rank Sector Weight
1 Healthcare 96.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALLK
51
DELISTED
Allakos
ALLK
$1.89M 0.2%
2,900,000
– –
NMRA icon
52
Neumora Therapeutics
NMRA
$311M
$1.32M 0.14%
100,000
-200,000
-67% -$2.33M
IOBT
53
DELISTED
IO Biotech
IOBT
$519K 0.06%
493,827
– –
SKYE icon
54
Skye Bioscience
SKYE
$21.6M
$391K 0.04%
100,000
-1,201,518
-92% -$6.74M
BOLD
55
Boundless Bio
BOLD
$55.5M
$204K 0.02%
58,903
-58,903
-50% -$213K
ANNX icon
56
CALL
Annexon
ANNX
$814M
– –
-1,500,000
Closed -$7.35M
APLS
57
DELISTED
Apellis Pharmaceuticals
APLS
– –
-400,000
Closed -$14.8M
APLT
58
DELISTED
Applied Therapeutics
APLT
– –
-600,000
Closed -$2.66M
ARGX icon
59
argenx
ARGX
$54.6B
– –
-135,000
Closed -$58.1M
BHVN icon
60
Biohaven
BHVN
$2.07B
– –
-250,000
Closed -$8.68M
ELEV
61
DELISTED
Elevation Oncology
ELEV
– –
-3,850,000
Closed -$10.4M
GPCR icon
62
CALL
Structure Therapeutics
GPCR
$3.4B
– –
-450,000
Closed -$17.7M
MLTX icon
63
MoonLake Immunotherapeutics
MLTX
$1.59B
– –
-750,000
Closed -$33M
NUVB.WS
64
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
– –
-66,666
Closed -$10.7K
RLAY icon
65
Relay Therapeutics
RLAY
$3.99B
– –
-1,300,000
Closed -$8.48M
RNAC icon
66
Cartesian Therapeutics
RNAC
$225M
– –
-90,000
Closed -$2.43M
SRPT icon
67
CALL
Sarepta Therapeutics
SRPT
$1.63B
– –
-500,000
Closed -$79M
STOK icon
68
Stoke Therapeutics
STOK
$1.83B
– –
-1,050,000
Closed -$14.2M
XBI icon
69
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
– –
-2,000,000
Closed -$185M
XENE icon
70
Xenon Pharmaceuticals
XENE
$6.28B
– –
-375,000
Closed -$14.6M
XNCR icon
71
Xencor
XNCR
$1.48B
– –
-1,500,000
Closed -$28.4M
1 2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q3 2024 Portfolio in Review

As of Q3 2024, Logos Global Management held 71 positions worth $927M, down 25% from $1.24B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Logos Global Management withdrew a net $340M in Q3 2024, closing 16 positions and reducing 19 holdings. Its most notable exit was argenx, an estimated $58.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 70% a quarter earlier.

Against the trend, Logos Global Management opened a new position in Celldex Therapeutics worth $30.6M.

  • Logos Global Management's largest Q3 2024 buy was Celldex Therapeutics: 900,000 shares worth $30.6M.
  • Logos Global Management added most to Ionis Pharmaceuticals in Q3 2024, an estimated $20.9M increase.
  • Logos Global Management's biggest Q3 2024 reduction was Silence Therapeutics, cutting an estimated $23.7M.
  • Logos Global Management fully exited argenx in Q3 2024, selling an estimated $58.1M.
  • Logos Global Management's ten largest holdings make up 47% of its $927M portfolio in Q3 2024.
  • Logos Global Management opened 14 new positions and closed 16 in Q3 2024.
  • Logos Global Management's portfolio value fell 25% quarter-over-quarter to $927M.

Based on Logos Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.